FDA Grants Expanded Early Access to Breakthrough Pancreatic Cancer Drug Daraxonrasib
The U.S. FDA approves expanded access to daraxonrasib, a breakthrough targeted therapy for previously treated metastatic pancreatic ductal adenocarcinoma, offering new hope for patients with one of the deadliest cancers.